Back to Search
Start Over
An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY).
- Source :
- Journal of Clinical Hypertension; Jun2008, Vol. 10 Issue 6, p436-442, 7p
- Publication Year :
- 2008
-
Abstract
- The Trial of Preventing Hypertension (TROPHY) demonstrated the feasibility of possibly reducing the incidence of hypertension with the angiotensin receptor blocker candesartan compared with placebo. The long-term benefits of pharmacologic therapy in high-normal blood pressure, or prehypertension are not known, and the long-term effect on health-related quality of life (HRQL) has not been determined. An analysis of covariance model was used to assess treatment differences from baseline in the HRQL scores using Short Form (SF)-36, and component measures at subsequent visits. Of the 809 randomized patients, 734 had both baseline and > or =1 HRQL follow-up assessment: 95% (379 of 397) of patients receiving candesartan and 91% (355 of 388) of patients receiving placebo. There were no statistically significant between-group differences in least-squares mean physical component survey and mental component survey scores or the individual scales at each scheduled visit relative to baseline values (P >.05). In TROPHY, patients with prehypertension had relatively high baseline HRQL, and HRQL was maintained with the angiotensin receptor blocker candesartan over both the 2-year treatment period and a total 4-year trial period. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 15246175
- Volume :
- 10
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- Journal of Clinical Hypertension
- Publication Type :
- Academic Journal
- Accession number :
- 105616671
- Full Text :
- https://doi.org/10.1111/j.1751-7176.2008.07837.x